Trump Media and Technology Group Corp vs Eli Lilly And Co — how do they compare? Trump Media and Technology Group Corp trades at $9.12 (market cap $2.50B), while Eli Lilly And Co trades at $1,140 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 412× Trump Media and Technology Group Corp's market cap, and Eli Lilly And Co pays a 0.6% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals.
| DJT | LLY | |
|---|---|---|
Market Cap | $2.50B | $1.03T |
Sector | Media | Health |
52-Week High | $19.86 | $1.24K |
52-Week Low | $7.06 | $625.65 |
Enterprise Value | $2.45B | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.52, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported minimal revenue of $3.68M in 2025 alongside a massive net loss of -$712.06M, reflecting severe profitability challenges. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of a Truth Social spin-off, while a merger with TAE Technologies aims to pivot toward nuclear fusion energy.
The outlook remains highly speculative, with the stock's meme-driven volatility and fundamental weaknesses posing significant risks. Investment opportunity hinges on successful execution of the TAE merger and fusion technology prospects, but persistent losses and high valuation ratios suggest substantial downside potential if growth fails to materialize.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →